A Phase 1 interventional study of PF-04856883 and PF-04856883 in Healthy, sponsored by Pfizer. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-07-31.
Sponsored by Pfizer · Phase 1 and Interventional
The purpose of the study is to further evaluate the PK characteristics of PF-04856883.
Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
-
Exclusion Criteria:
-
Biological: PF-04856883
Biological: PF-04856883
Biological: PF-04856883
Biological: PF-04856883
Dose A
Dose B
Dose C
Dose D
PF-04856883 Pharmacokinetics including Cmax, Tmax, AUCo-infinity, AUClast, Cl/F, Vz/F and t1/2
Time frame: 4 weeks
Number of subjects with AEs reported
Time frame: 4 weeks
Number of subjects with abnormal physical examination findings
Time frame: 4 weeks
Number of subjects with abnormal clinical laboratory results
Time frame: 4 weeks
Number of subjects with abnormal ECGs
Time frame: 4 weeks
Number of subjects with abnormal vital signs
Time frame: 4 weeks
This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer